Patents Assigned to Nihon Medi-Physics Co., Ltd.
-
Patent number: 9387266Abstract: It is intended to provide a novel amino acid organic compound which can be used as a labeling precursor compound for radioactive halogen-labeled amino acid compounds including [18F]FACBC, and which prevents methanol from remaining in the radioactive halogen-labeled amino acid compounds produced therefrom. The novel amino acid organic compound is a compound represented by the following formula: wherein n is an integer of 0 or of 1 to 4; R1 is an ethyl, 1-propyl or isopropyl substituent; X is a halogen substituent or a group represented by —OR2; R2 is a straight-chain or branched-chain haloalkylsulfonic acid substituent with one to 10 carbon atoms, trialkylstannyl substituent with 3 to 12 carbon atoms, fluorosulfonic acid substituent or aromatic sulfonic acid substituent; and R3 is a protective group.Type: GrantFiled: August 21, 2015Date of Patent: July 12, 2016Assignee: NIHON MEDI-PHYSICS CO., LTD.Inventors: Osamu Ito, Akio Hayashi, Fumie Kurosaki, Masahito Toyama, Toshiyuki Shinmura, Arinori Harano
-
Patent number: 9381259Abstract: It is intended to provide a novel amino acid organic compound which can be used as a labeling precursor compound for radioactive halogen-labeled amino acid compounds including [18F]FACBC, and which prevents methanol from remaining in the radioactive halogen-labeled amino acid compounds produced therefrom. The novel amino acid organic compound is a compound represented by the following formula: wherein n is an integer of 0 or of 1 to 4; R1 is an ethyl, 1-propyl or isopropyl substituent; X is a halogen substituent or a group represented by —OR2; R2 is a straight-chain or branched-chain haloalkylsulfonic acid substituent with one to 10 carbon atoms, trialkylstannyl substituent with 3 to 12 carbon atoms, fluorosulfonic acid substituent or aromatic sulfonic acid substituent; and R3 is a protective group.Type: GrantFiled: April 7, 2014Date of Patent: July 5, 2016Assignee: NIHON MEDI-PHYSICS CO., LTD.Inventors: Osamu Ito, Akio Hayashi, Fumie Kurosaki, Masahito Toyama, Toshiyuki Shinmura, Arinori Harano
-
Patent number: 9211350Abstract: A compound represented by the following formula (1), or a salt thereof: wherein R1 is a radioactive halogen substituent, 0 to 2 of A1, A2, A3 and A4 represent N, and the rest represent —(CH)— is effective as a diagnostic imaging probe targeting amyloid. A diagnostic agent for Alzheimer's disease contains a compound represented by the above formula (1) or a salt thereof. After administration to a patient, the compound and the diagnostic agent for Alzheimer's disease transfer into the patient's brain, and indicate good accumulation on amyloid deposited in the brain.Type: GrantFiled: May 29, 2012Date of Patent: December 15, 2015Assignee: NIHON MEDI-PHYSICS CO., LTD.Inventors: Yuki Okumura, Yoshifumi Maya, Yoshinari Shoyama, Takako Onishi
-
Patent number: 9202293Abstract: Contour information is extracted from nuclear medicine projection data on a subject not subjected to a scattering correction and an absorption correction by performing a pixel value binarization processing based on a threshold scheme. If necessary, an interpolation processing is performed before reconstructing an image through an image reconstruction processing. Based on the reconstructed image, a second binarization processing is performed to generate a contour image.Type: GrantFiled: May 6, 2013Date of Patent: December 1, 2015Assignees: Nihon Medi-Physics Co., Ltd., National Cerebral and Cardiovascular CenterInventors: Hidehiro Iida, Mayumi Nakazawa
-
Patent number: 9149546Abstract: A compound that is effective as a diagnostic imaging probe that targets amyloid including is represented by the following formula (1), or salt thereof: wherein R1 is a radioactive halogen substituent, A1 and A2 independently represent CH or N. A diagnostic agent for Alzheimer's disease includes the compound represented by the above formula or a salt thereof. The above compound and the above diagnostic agent for Alzheimer's disease transfer into brain after administration, and indicate good accumulation on amyloid deposited in the brain.Type: GrantFiled: May 18, 2012Date of Patent: October 6, 2015Assignee: NIHON MEDI-PHYSICS CO., LTD.Inventors: Yuki Okumura, Yoshifumi Maya, Yoshinari Shoyama, Takako Onishi
-
Patent number: 9129373Abstract: A measuring image acquisition means 2 acquires a 3-D measuring image in which a phantom filled with the radioactive material into a necessary part is measured with a SPECT system. A measuring image Fourier transform means 4 operates the 3-D measuring image with the 3-D Fourier transform. An actual image acquisition means 6 acquires a 3-D actual image of the part of the phantom which is filled with the radioactive material. An actual image Fourier transform means 8 operates a 3-D actual image with the 3-D Fourier transform. An error image calculation means 10 divides each Fourier transform value of the 3-D Fourier transform measuring image by each Fourier transform value of the corresponding 3-D Fourier transform actual image and acquires a 3-D Fourier transform error image. A point spread function calculation means 12 operates the 3-D Fourier transform error image with the inverse Fourier transform and determines the point spread function image by calculation.Type: GrantFiled: September 25, 2012Date of Patent: September 8, 2015Assignees: NIHON MEDI-PHYSICS CO., LTD., NATIONAL CEREBRAL AND CARDIOVASCULAR CENTERInventors: Hidehiro Iida, Tsutomu Zeniya, Yuki Hori, Mayumi Nakazawa
-
Patent number: 9107964Abstract: The present invention is a compound represented by the following formula (1) or a salt thereof. In the formula (1), R1 denotes a hydrogen atom, a methyl group, or a hydroxymethyl group, and n is an integer of 1 or 2.Type: GrantFiled: September 18, 2012Date of Patent: August 18, 2015Assignees: NIHON MEDI-PHYSICS CO., LTD., NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITYInventors: Norihito Nakata, Yuki Okumura, Masato Kiriu, Eriko Nagata, Hiroki Matsumoto, Yuji Kuge, Songji Zhao, Ken-Ichi Nishijima
-
Patent number: 9044520Abstract: Embodiments of the invention provide a compound accumulating in an inflammatory site, a diagnostic agent containing the compound in labeled state and its precursor compound for labeling. Such a compound accumulating in inflammatory site may be represented by the following formula (1): Z—Y-Leu-Phe-(X)n-DLys(-(DLys)m-HalB)-(DLys)k-NH2??(1) wherein in the formula (1), Z represents a protective group for an amino group; Y represents Met or Nle; X represents a spacer consisting of one or more of amino acid and/or synthetic organic compounds; n represents 1 or 0; m represents 1 or 0; k represents 1 or 0; and HalB represents a substituted benzoic acid having a radioactive halogen in an aromatic ring.Type: GrantFiled: March 29, 2012Date of Patent: June 2, 2015Assignees: Nihon Medi-Physics Co., Ltd., Kyoto UniversityInventors: Hideo Saji, Hiroyuki Kimura, Masahiro Ono, Ikuya Seki
-
Publication number: 20140213817Abstract: It is intended to provide a novel amino acid organic compound which can be used as a labeling precursor compound for radioactive halogen-labeled amino acid compounds including [18F]FACBC, and which prevents methanol from remaining in the radioactive halogen-labeled amino acid compounds produced therefrom. The novel amino acid organic compound is a compound represented by the following formula: wherein n is an integer of 0 or of 1 to 4; R1 is an ethyl, 1-propyl or isopropyl substituent; X is a halogen substituent or a group represented by —OR2; R2 is a straight-chain or branched-chain haloalkylsulfonic acid substituent with one to 10 carbon atoms, trialkylstannyl substituent with 3 to 12 carbon atoms, fluorosulfonic acid substituent or aromatic sulfonic acid substituent; and R3 is a protective group.Type: ApplicationFiled: April 7, 2014Publication date: July 31, 2014Applicant: Nihon-Medi-Physics Co., Ltd.Inventors: Osamu ITO, Akio Hayashi, Fumie Kurosaki, Masahito Toyama, Toshiyuki Shinmura, Arinori Harano
-
Patent number: 8790620Abstract: A composition including a radioactive fluorine-labeled amino acid compound is provided, which can be prevented from radiolysis. Disclosed is a composition which includes a solution containing a radioactive fluorine-labeled amino acid compound as an effective ingredient, in which the pH value of the solution is kept at 2.0-5.9, more preferably 2.0-4.9 in order to inhibit radiolysis. Also, it is possible to further inhibit radiolysis by adding thereto a pharmaceutical additive capable of inhibiting radiolysis, such as a sugar, a sugar alcohol and a sugar lactone, while the pH is kept at 2.0-5.9.Type: GrantFiled: November 20, 2007Date of Patent: July 29, 2014Assignee: Nihon Medi-Physics Co., Ltd.Inventors: Akio Hayashi, Toshiyuki Shinmura, Daisaku Nakamura, Soichi Takasaki, Shinji Tokunaga, Emi Kaneko, Masahito Toyama
-
Publication number: 20140186260Abstract: A radiopharmaceutical comprising combination of a particular radioactive dithiosemicarbazone copper complex, and a chelating agent comprising a multidentate ligand having a maximum dentate number of 2 or more to 4 or less.Type: ApplicationFiled: December 24, 2013Publication date: July 3, 2014Applicants: NIHON MEDI-PHYSICS CO., LTD., NATIONAL CANCER CENTER, NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCESInventors: Yukie YOSHII, Hiroki Matsumoto, Mitsuyoshi Yoshimoto
-
Publication number: 20140186261Abstract: An anti-tumor agent comprising combination of a radioactive diacetyl-bis(N4-methylthiosemicarbazone) copper complex and a metabolic inhibitor.Type: ApplicationFiled: December 24, 2013Publication date: July 3, 2014Applicants: NIHON MEDI-PHYSICS CO., LTD., NATIONAL CANCER CENTER, NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCESInventors: Yukie YOSHII, Takako Furukawa, Tsuneo Saga, Hiroki Matsumoto, Mitsuyoshi Yoshimoto
-
Publication number: 20140187784Abstract: It is intended to provide a radioactive compound that has higher selectivity for CYP11B2 than that for CYP11B1, exhibits highly selective accumulation in the adrenal gland compared with blood and organs adjacent to the adrenal gland, and permits commercial supply. The present invention provides a radioactive quinolinone derivative represented by the predetermined general formula or a salt thereof.Type: ApplicationFiled: December 19, 2013Publication date: July 3, 2014Applicants: Nihon Medi-Physics Co., Ltd., Kyoto UniversityInventors: Hideo Saji, Hiroyuki Kimura, Masahiro Ono, Hiroki Matsumoto
-
Patent number: 8758724Abstract: It is intended to provide a novel amino acid organic compound which can be used as a labeling precursor compound for radioactive halogen-labeled amino acid compounds including [18F]FACBC, and which prevents methanol from remaining in the radioactive halogen-labeled amino acid compounds produced therefrom. The novel amino acid organic compound is a compound represented by the following formula: wherein n is an integer of 0 or of 1 to 4; R1 is an ethyl, 1-propyl or isopropyl substituent; X is a halogen substituent or a group represented by —OR2; R2 is a straight-chain or branched-chain haloalkylsulfonic acid substituent with one to 10 carbon atoms, trialkylstannyl substituent with 3 to 12 carbon atoms, fluorosulfonic acid substituent or aromatic sulfonic acid substituent; and R3 is a protective group.Type: GrantFiled: November 28, 2006Date of Patent: June 24, 2014Assignee: Nihon Medi-Physics Co., Ltd.Inventors: Osamu Ito, Akio Hayashi, Fumie Kurosaki, Masahito Toyama, Toshiyuki Shinmura, Arinori Harano
-
Patent number: 8693746Abstract: In one embodiment of the present invention, a significance test of pixel values is performed between a region where functions could be deteriorated in a disease-specific manner and a region where functions could be preserved even in cases of diseases using brain functional images. Then, the mean pixel value of the functionally preserved site is significantly greater than the mean pixel value of the functionally deteriorated site according to the significance test is determined as an a image including a neurodegenerative disorder. According to this embodiment, it becomes possible to objectively detect images of neurodegenerative disorders without using a database for healthy subjects.Type: GrantFiled: July 28, 2008Date of Patent: April 8, 2014Assignee: Nihon Medi-Physics Co., Ltd.Inventor: Kazunari Ishii
-
Publication number: 20140088306Abstract: Provided is a compound effective as a diagnostic imaging probe targeting amyloid and an agent for Alzheimer's disease diagnosis including the compound.Type: ApplicationFiled: August 26, 2013Publication date: March 27, 2014Applicants: Nihon Medi-Physics Co., Ltd., KYOTO UNIVERSITYInventors: Hideo Saji, Masahiro Ono, Masafumi Ihara, Ikuya Seki
-
Patent number: 8658132Abstract: A method for producing a radioactive diagnostic imaging agent containing a radioactive 18 fluorine-labeled organic compound represented by the following formula (1): as an effective ingredient in which radiolysis of the effective ingredient is inhibited, involves providing a solution containing the radioactive 18fluorine-labeled organic compound represented by the above formula (1), adding an acid to the solution obtained in the first step in an amount sufficient for the solution to be kept within a pH of 2.0-5.9 in the following third step, and diluting the solution obtained in the second step in order to adjust the solution to a desired radioactive concentration within a pH of 2.0-5.9.Type: GrantFiled: August 2, 2012Date of Patent: February 25, 2014Assignee: Nihon Medi-Physics Co., Ltd.Inventors: Daisaku Nakamura, Soichi Nakamura, Masahito Toyama, Akio Hayashi
-
Publication number: 20130294671Abstract: Contour information is extracted from nuclear medicine projection data on a subject not subjected to a scattering correction and an absorption correction by performing a pixel value binarization processing based on a threshold scheme. If necessary, an interpolation processing is performed before reconstructing an image through an image reconstruction processing. Based on the reconstructed image, a second binarization processing is performed to generate a contour image.Type: ApplicationFiled: May 6, 2013Publication date: November 7, 2013Applicants: Nihon Medi-Physics Co., Ltd., National Cerebral and Cardiovascular CenterInventors: HIDEHIRO IIDA, MAYUMI NAKAZAWA
-
Patent number: 8563771Abstract: A process is provided for producing a labeled precursor which is useful for production of a radioactive fluorine-labeled amino acid compound. In the reaction step for introducing a leaving group to a mixture of syn-form and anti-form of FACBC, a base is allowed to present in the reaction system to produce a syn-leaving group adduct, which is unreactive with the base and is highly stable, and an anti-leaving group adduct which can react with the base to form a water-soluble compound. By employing a purification method utilizing such a difference in solubility, the syn-leaving group adduct can be separated selectively. The base may be a linear- or branched-chain primary to tertiary alkylamine having 1 to 10 carbon atoms, a nitrogen-containing heterocyclic compound with 2 to 20 carbon atoms, and a nitrogen-containing hetero aromatic compound with 2 to 20 carbon atoms.Type: GrantFiled: December 17, 2007Date of Patent: October 22, 2013Assignee: Nihon Medi-Physics Co., Ltd.Inventors: Masahito Toyama, Akio Hayashi
-
Publication number: 20130251226Abstract: A measuring image acquisition means 2 acquires a 3-D measuring image in which a phantom filled with the radioactive material into a necessary part is measured with a SPECT system. A measuring image Fourier transform means 4 operates the 3-D measuring image with the 3-D Fourier transform. An actual image acquisition means 6 acquires a 3-D actual image of the part of the phantom which is filled with the radioactive material. An actual image Fourier transform means 8 operates a 3-D actual image with the 3-D Fourier transform. An error image calculation means 10 divides each Fourier transform value of the 3-D Fourier transform measuring image by each Fourier transform value of the corresponding 3-D Fourier transform actual image and acquires a 3-D Fourier transform error image. A point spread function calculation means 12 operates the 3-D Fourier transform error image with the inverse Fourier transform and determines the point spread function image by calculation.Type: ApplicationFiled: September 25, 2012Publication date: September 26, 2013Applicants: NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER, NIHON MEDI-PHYSICS CO., LTD.Inventors: Hidehiro IIDA, Tsutomu ZENIYA, Yuki HORI, Mayumi NAKAZAWA